We have located links that may give you full text access.
The mitral valve replacement by the new-type bioprostheses (features of design and long-term results).
Journal of Cardiovascular Surgery 1994 December
The BAKS bioprostheses were created in our centre and they have the following features: (1) to reduce immunogenicity they underwent a combined fermentochemical treatment which resulted in the native xenovalve consisting of collagen and elastic fibres only; (2) in cutting out the valve the natural aortic sinuses were preserved; and (3) the xenovalve was fixed on a functional frame of an original design. From 1979, BAKS have been implanted in 243 patients with the isolated mitral valve reumatic injury. The patients age varied from 11 to 59 years; 91 patients (37.5%) were under 35 years. The 12-year survival rate (without hospital lethality) was 65.5 +/- 5.3%. The most serious longterm complications were: infectious endocarditis (3.14 patients/years); spontaneous degeneration of bioprosthetic cusps (2.24% patients/years); thromboembolism (0.6% patients/years). The morphological examination of bioprostheses removed in reoperations from 10 days to 10 years after implantation was performed in 51 cases. Most often, collagen degeneration occurred in patients under 35. The pathologic structural changes originated because of the localized saturation of bioprosthetic cusps with the recipient plasma proteins, gradual disintegration of collagen fibres, and further calcification of that area. The indications to the mitral valve replacement by BAKS were: the left atrium thrombosis, thromboembolytic syndrome, contraindications to anticoagulation therapy, and the age over 35 years.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app